Nippon Shinyaku Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial ReportiCD ResearchFebruary 2, 2012 38 Pages - SKU: ICDR6792936 |
| Synopsis ICD Research's Nippon Shinyaku Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report contains in depth information and data about the company and its operations. The profile contains a company overview, business description, competitive benchmarking, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company. Summary ICD Research's Nippon Shinyaku Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report is a crucial resource for industry executives and anyone looking to access key information about Nippon Shinyaku Co., Ltd.. ICD Research's Nippon Shinyaku Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Scope
Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) specializes in the development, manufacture and sale of ethical drugs. The company manufactures and sells a wide range of drugs for the treatment of urological diseases, allergies, inflammation, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders and others. In addition, the company develops, produces and sells functional foods and ingredients such as protein preparations, agents for improving food shelf life and health food ingredients. It operates in the regions of Germany, Japan, and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan. |
Related Markets
Pharmaceuticals Company Reports
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012
- Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics
- Partnerships, Licensing, Investments and M&A Deals and Trends for March 2012 in Pharmaceuticals
- Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

